Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.
By D. Jayne, G. Gaskin, N. Rasmussen, D. Abramowicz, F. Ferrario, L. Guillevin, E. Mirapeix, C. Savage, R. Sinico, C. Stegeman and 4 more. Journal of the American Society of Nephrology, 2007
1,071 citations recorded by the source corpus.
Subfields: Nephrology, Pulmonary and Respiratory Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/eba05749507eb056f086687d73049726aa5e92af
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Rheumatology
Citations in the corpus
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue (2019, neutral): “References [105–127]”
- Long-term patient survival in ANCA-associated vasculitis (2010, background): “Four randomised controlled trials were launched to study treatment regimens tailored to different disease stages in patients with newly diagnosed ANCA-associated vasculitis.”
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of ANCA-Associated Vasculitis (2021, neutral): “8 mg/ dl for entry, showed that plasma exchange decreased the risk of ESRD but did not decrease mortality (13,14).”
- KDIGO Clinical Practice Guideline for Glomerulonephritis (2012, methodology): “The only randomized evaluation of pulse methylprednisolone (3 1000 mg) was in the setting of the MEPEX trial, where it was compared to plasmapheresis as adjunctive therapy to oral corticosteroids and oral cyclophosphamide.(707) In that trial, pulse methylprednisolone was less efficacious than plasma”
- EULAR recommendations for the management of primary small and medium vessel vasculitis (2008, background): “34 It has not been shown to improve overall survival and it is not known whether or not it benefits patients with less severe disease.”
- EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (2016, neutral): “7 mg/dL) or those requiring dialysis (77).”